As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 8,241,000 cases in 2023. These cases are projected to increase during the forecast period, i.e., ...
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...
At the San Antonio Breast Cancer Symposium (SABCS), investigators outlined the rationale and design of the ERADICATE, a first ...
Investigator sought to compare treatment strategies that omit chemotherapy and/or include ribociblib against standard treatment for safety and efficacy.
The discovery could pave the way for new treatments, improved risk prediction, and earlier intervention for brain metastases.
Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and ...
The HER2CLIMB-05 study assessed the efficacy and safety of adding tucatinib to maintenance therapy with trastuzumab/pertuzumab in patients with HER2+ metastatic breast cancer.
Z-endoxifen has demonstrated efficacy in phase 1 and 2 trials, improving progression-free survival and tumor response in ...
People living with metastatic breast cancer have more treatment options today than ever before. At Fred Hutch Cancer Center, we provide the latest in evidence-based care, including a wide range of ...
GlobalData on MSN
HUTCHMED begins Phase III segment of metastatic PDAC treatment trial
HUTCHMED has commenced the Phase III stage of its ongoing Phase II/III clinical trial assessing the combination of ...
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...
From hair regrowth to safe pregnancy chemotherapy and new targeted therapies, these top five breast cancer stories of 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback